A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of RSS0393 Ointment in Adults With Mild to Moderate Atopic Dermatitis
Latest Information Update: 05 May 2026
At a glance
- Drugs RSS 0393 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Reistone Biopharma
Most Recent Events
- 29 Apr 2026 Status changed from active, no longer recruiting to completed.
- 29 Jan 2026 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2025 Status changed from not yet recruiting to recruiting.